172 related articles for article (PubMed ID: 16216498)
1. Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.
Martina E; Stiefl N; Degel B; Schulz F; Breuning A; Schiller M; Vicik R; Baumann K; Ziebuhr J; Schirmeister T
Bioorg Med Chem Lett; 2005 Dec; 15(24):5365-9. PubMed ID: 16216498
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.
Shie JJ; Fang JM; Kuo CJ; Kuo TH; Liang PH; Huang HJ; Yang WB; Lin CH; Chen JL; Wu YT; Wong CH
J Med Chem; 2005 Jun; 48(13):4469-73. PubMed ID: 15974598
[TBL] [Abstract][Full Text] [Related]
3. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
[TBL] [Abstract][Full Text] [Related]
4. The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease.
Ren Z; Yan L; Zhang N; Guo Y; Yang C; Lou Z; Rao Z
Protein Cell; 2013 Apr; 4(4):248-50. PubMed ID: 23549610
[No Abstract] [Full Text] [Related]
5. A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods.
Kaeppler U; Stiefl N; Schiller M; Vicik R; Breuning A; Schmitz W; Rupprecht D; Schmuck C; Baumann K; Ziebuhr J; Schirmeister T
J Med Chem; 2005 Nov; 48(22):6832-42. PubMed ID: 16250642
[TBL] [Abstract][Full Text] [Related]
6. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
7. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.
Wang L; Bao BB; Song GQ; Chen C; Zhang XM; Lu W; Wang Z; Cai Y; Li S; Fu S; Song FH; Yang H; Wang JG
Eur J Med Chem; 2017 Sep; 137():450-461. PubMed ID: 28624700
[TBL] [Abstract][Full Text] [Related]
8. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
Ramajayam R; Tan KP; Liu HG; Liang PH
Bioorg Med Chem; 2010 Nov; 18(22):7849-54. PubMed ID: 20947359
[TBL] [Abstract][Full Text] [Related]
10. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.
Lu IL; Mahindroo N; Liang PH; Peng YH; Kuo CJ; Tsai KC; Hsieh HP; Chao YS; Wu SY
J Med Chem; 2006 Aug; 49(17):5154-61. PubMed ID: 16913704
[TBL] [Abstract][Full Text] [Related]
11. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays.
Chen L; Chen S; Gui C; Shen J; Shen X; Jiang H
J Biomol Screen; 2006 Dec; 11(8):915-21. PubMed ID: 17092912
[TBL] [Abstract][Full Text] [Related]
12. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
[TBL] [Abstract][Full Text] [Related]
13. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
[TBL] [Abstract][Full Text] [Related]
14. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
Schirmeister T
J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor design for SARS coronavirus main protease based on "distorted key theory".
Du QS; Sun H; Chou KC
Med Chem; 2007 Jan; 3(1):1-6. PubMed ID: 17266617
[TBL] [Abstract][Full Text] [Related]
17. Drug design targeting the main protease, the Achilles' heel of coronaviruses.
Yang H; Bartlam M; Rao Z
Curr Pharm Des; 2006; 12(35):4573-90. PubMed ID: 17168763
[TBL] [Abstract][Full Text] [Related]
18. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features.
Chen L; Li J; Luo C; Liu H; Xu W; Chen G; Liew OW; Zhu W; Puah CM; Shen X; Jiang H
Bioorg Med Chem; 2006 Dec; 14(24):8295-306. PubMed ID: 17046271
[TBL] [Abstract][Full Text] [Related]
19. Topological analysis of SARS CoV-2 main protease.
Estrada E
Chaos; 2020 Jun; 30(6):061102. PubMed ID: 32611087
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.
Blanchard JE; Elowe NH; Huitema C; Fortin PD; Cechetto JD; Eltis LD; Brown ED
Chem Biol; 2004 Oct; 11(10):1445-53. PubMed ID: 15489171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
